We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Beneficial Effect Of T-1095, A Selective Inhibitor Of Renal Na<sup>+</sup> –Glucose Cotransporters, On Metabolic Index And Insulin Secretion In Spontaneously Diabetic Gk Rats.
- Authors
Nunoi, Kumiko; Yasuda, Koichiro; Adachi, Tetsuya; Okamoto, Yoshimasa; Shihara, Nobuyuki; Uno, Mika; Tamon, Akiko; Suzuki, Naoko; Oku, Akira; Tsuda, Kinsuke
- Abstract
SUMMARY 1. To investigate the pharmacological effects of T-1095, this novel derivative of phlorizin was administered to GK rats for 8 weeks. T-1095 treatment significantly lowered plasma glucose and glycosylated haemoglobin (HbA1c ) levels, but did not significantly affect bodyweight. 2. T-1095 treatment did not affect 3.3 mmol/L glucose-induced insulin secretion in the isolated perfused pancreas of GK rats. 3. The peak insulin release in T-1095-treated GK rats was significantly higher during the first phase than in untreated GK rats (3–4 min after beginning 16.7 mmol/L glucose perfusion). The total amount of insulin secreted during the first phase in T-1095-treated GK rats was significantly higher than in untreated GK rats (35.3 ± 1.4 vs 27.3 ± 2.5 ng in T-1095-treated compared with untreated rats, respectively). 4. During the second phase, insulin release in T-1095-treated GK rats was somewhat higher than in untreated GK rats (7–30 min after beginning 16.7 mmol/L glucose perfusion). The total amount of insulin secreted during the second phase in T-1095-treated GK rats was significantly higher than in untreated GK rats (88.2 ± 6.1 vs 68.1 ± 5.7 ng, respectively). 5. The total amount of insulin secreted during perfusion in T-1095-treated GK rats was significantly higher than in untreated GK rats (123.5 ± 7.3 vs 95.4 ± 7.7 ng, respectively). 6. These data show that the metabolic indices, plasma glucose and HbA1c levels and insulin secretion are significantly improved by T-1095 treatment in GK rats, which are spontaneously diabetic rats, suggesting its usefulness as a novel oral therapeutic antidiabetic agent.
- Subjects
TYPE 2 diabetes; INSULIN; PERFUSION; PANCREAS
- Publication
Clinical & Experimental Pharmacology & Physiology, 2002, Vol 29, Issue 5/6, p386
- ISSN
0305-1870
- Publication type
Article
- DOI
10.1046/j.1440-1681.2002.03671.x